Charles River Laboratories International Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Charles River Laboratories International Inc Unternehmen

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Inc Informationen



BörsenkürzelCRL

Name des UnternehmensCharles River Laboratories International Inc

IPO-datumJun 23, 2000

CEOFoster (James C)

Anzahl der mitarbeiter18600

WertpapierartOrdinary Share

GeschäftsjahresendeJun 23

Addresse251 Ballardvale St

StadtWILMINGTON

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl01887

Telefon17812226000

Websitehttps://www.criver.com/

BörsenkürzelCRL

IPO-datumJun 23, 2000

CEOFoster (James C)

Führungskräfte von Charles River Laboratories International Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. James C. Foster

Chairman of the Board, President, Chief Executive Officer

276.94K

+0.67%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

54.42K

-17.91%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

16.96K

-27.32%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

16.05K

+19.74%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

10.87K

-45.20%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

6.35K

+22.65%

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

5.40K

+26.62%

Ms. Reshema Kemps-Polanco

Independent Director

4.56K

+43.24%

Dr. Craig B. Thompson, M.D.

Independent Director

3.85K

+37.34%

Mr. Abraham N. (Abe) Ceesay

Independent Director

2.38K

+60.32%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. James C. Foster

Chairman of the Board, President, Chief Executive Officer

276.94K

+0.67%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

54.42K

-17.91%

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

16.96K

-27.32%

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

16.05K

+19.74%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

10.87K

-45.20%

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

6.35K

+22.65%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

DSA

2.40B

59.84%

RMS

846.08M

21.07%

Manufacturing

766.41M

19.09%

Nach RegionUSD

Name

Umsatz

Anteil

United States

2.14B

53.34%

Europe

1.10B

27.46%

Canada

501.02M

12.48%

Asia Pacific (Region)

205.02M

5.11%

Other

64.86M

1.62%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

DSA

2.40B

59.84%

RMS

846.08M

21.07%

Manufacturing

766.41M

19.09%

Aktionärsstatistik

Aktualisiert: Thu, May 14

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Vanguard Capital Management, LLC

6.65%

BlackRock Institutional Trust Company, N.A.

5.97%

Vanguard Portfolio Management, LLC

4.76%

Allspring Global Investments, LLC

4.14%

State Street Investment Management (US)

3.89%

Andere

74.59%

Aktionäre

Anteil

Vanguard Capital Management, LLC

6.65%

BlackRock Institutional Trust Company, N.A.

5.97%

Vanguard Portfolio Management, LLC

4.76%

Allspring Global Investments, LLC

4.14%

State Street Investment Management (US)

3.89%

Andere

74.59%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

50.79%

Investment Advisor/Hedge Fund

50.41%

Hedge Fund

9.44%

Research Firm

2.78%

Pension Fund

1.52%

Sovereign Wealth Fund

1.01%

Individual Investor

0.95%

Bank and Trust

0.75%

Family Office

0.09%

Institutionelle Beteiligung



Aktualisiert: Sun, Apr 5

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

1429

56.13M

116.51%

-7.96M

2025Q4

1367

52.25M

129.09%

+28.56K

2025Q3

1413

52.22M

129.54%

+64.86K

2025Q2

1411

52.12M

127.74%

-2.86M

2025Q1

1414

54.69M

123.53%

-5.98M

2024Q4

1410

54.25M

114.75%

+1.17M

2024Q3

1372

53.38M

114.53%

-33.66K

2024Q2

1378

53.46M

111.45%

+347.48K

2024Q1

1371

53.18M

111.09%

-4.05M

2023Q4

1405

52.96M

112.24%

-202.82K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

2.88M

5.85%

+56.48K

+2.00%

Dec 31, 2025

Allspring Global Investments, LLC

2.00M

4.05%

-182.34K

-8.37%

Dec 31, 2025

State Street Investment Management (US)

1.87M

3.8%

+40.53K

+2.21%

Dec 31, 2025

Invesco Advisers, Inc.

1.78M

3.61%

+1.63M

+1113.97%

Dec 31, 2025

Wellington Management Company, LLP

1.75M

3.55%

-1.44M

-45.17%

Dec 31, 2025

Harris Associates L.P.

1.68M

3.41%

+204.52K

+13.88%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

1.44M

2.93%

+311.32K

+27.53%

Dec 31, 2025

Fidelity Management & Research Company LLC

1.55M

3.15%

+1.15M

+293.11%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Invesco S&P 500 Equal Weight Health Care ETF

1.92%

Schwab Ariel Opportunities ETF

1.82%

iShares Health Innovation Active ETF

1.74%

First Trust NASDAQ Pharmaceuticals ETF

1.71%

ROBO Global Healthcare Technology & Innovation ETF

1.69%

VanEck Biotech ETF

1.44%

Franklin Genomic Advancements ETF

1.42%

WisdomTree US Value Fund

1.15%

Invesco S&P 500 High Beta ETF

1.14%

Pacer Lunt Large Cap Alternator ETF

0.97%

Invesco S&P 500 Equal Weight Health Care ETF

Anteil1.92%

Schwab Ariel Opportunities ETF

Anteil1.82%

iShares Health Innovation Active ETF

Anteil1.74%

First Trust NASDAQ Pharmaceuticals ETF

Anteil1.71%

ROBO Global Healthcare Technology & Innovation ETF

Anteil1.69%

VanEck Biotech ETF

Anteil1.44%

Franklin Genomic Advancements ETF

Anteil1.42%

WisdomTree US Value Fund

Anteil1.15%

Invesco S&P 500 High Beta ETF

Anteil1.14%

Pacer Lunt Large Cap Alternator ETF

Anteil0.97%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten